Enfin disponible en Europe, grâce à une étonnante formule Europe, 100% naturelle, vous pouvez maintenant dire stop à vos problèmes d’impuissance et à vos troubles de la virilité. Cette formule révolutionnaire agit comme un véritable achat levitra
naturel. Ses résultats sont immédiats, sans aucun effet secondaire et vos érections sont durables, quelque soit votre âge. Même si vous avez plus de 50 ans !
D:\data 2013\rsp\cipla - rsp - 120413.pmd
Cipla - Gathering momentum
Cipla is one of the biggest players in Indian formulations market enjoying 5.7%
market share. Key therapies for the Company in the domestic space include:
Respiratory, Anti-Infective, Cardiac, Gynecology and GI. The Company has 70%
market share in Inhaler segment and its key brands in the same segment are:
Seroflo, Foracort, Budecort and Aerocort. In the export space, the Company has
been working on a low risk, low margin partnership model, which restricts any
margin upside in US & EU. However, the Company is consciously changing its
policy towards a more profitable model for the same. Cipla is now focusing on the
inhaler opportunity, which is expected to yield significant profitability, going ahead.
The recently commissioned Indore SEZ will be instrumental in fulfilling Cipla's
ambitions to fulfill its strong growth projections in ensuing times.
Outlook and Valuations
Though Cipla has underperformed the broader markets over the last 3 years, we
believe that operational improvement is likely to drive the growth over the next 2
years. Its outstanding performance in 9MFY2013 is symbolic of an inflection point
in the company's growth trajectory. Cipla's recent performance has been driven
by culmination of multiple strategic changes executed by the senior management
over the last couple of years, and we believe, it is sustainable. Cipla has worked
on four key aspects: a) rationalization of low-margin business and increased focus
on profitability; b) cash flow improvement; c) intent to establish front-ends in select
international markets; and d) professionals' hiring at top management. With updated
assumptions, we believe that the stock has an upside potential of 15-20% over the
Risks to the view
NPPA demand for alleged overpricing:
Cipla is currently fighting in High Court
against NPPA on account of alleged overpricing of essential drugs. It has
received a demand notice of Rs12,300cr under DPCO Act. If Cipla loses the
case, the penalty charges could adversely impact its cash flows as well as
Cipla's ~50% of revenue comes from the export markets,
making it susceptible towards currency fluctuation. Cipla follows a policy on
hedging the risk through forwards covering the receivables regularly. Any
adverse movement in the currency could affect the revenue and consequently
Impact of new pharma pricing policy:
~46% of the total sales come from
domestic formulations. Implementation of new pricing policy is likely to impact
Why Cipla (Investment arguments)
Combination inhaler launches in EU to drive growth from FY2014E onwards
According to Cipla management, the share of inhalers to exports has increased to 15% in
FY2012 from 10-12% earlier. The global market for respiratory products is over US$25bn
(largely dominated by combination inhaler products). The combination inhalers market is
worth US$12bn divided between 2 brands - Advair/Seretide (GSK) and Symbicort
(AstraZeneca). While the combination inhalers remain the largest market segment, it also
poses challenges for generic entry primarily due to higher investments and evolving
regulatory pathway. This makes the market a highly profitable one with fewer competitors.
Cipla has already launched four inhaler products in EU (market size of ~US$3bn) from a
total pipeline of 11 filings, namely, Budesonide, Salbutamol, Beclomethasone and
Salmeterol. The company expects to receive 3-4 more approvals for inhaler products in
the next two years, which could result in significant pick up in exports.
Restructuring at exports front contributes to growth
Cipla has undertaken a restructuring of its export portfolio for the past 2 years and has
been targeting niche segments such as inhalers (EU) and rationalization in ROW markets
(Africa, Australasia and Middle East markets). Also, taking a digression from its usual
strategy, Cipla now plans to file ANDAs on its own (vis-à-vis the partnership route followed
earlier) in the US market. It has already filed 5 ANDAs in 9MFY2013. A potential US
market success can add significant value to the stock, in our view.
Respiratory & Gynecology to sustain domestic growth
Cipla's reach from Tier-II to Tier-VI cities is formidable and is better than any of its listed
peers. Its pan-India presence with 7,000 field force and 58% portfolio in acute segment
will be the major growth drivers. Its niche therapeutic segments - Respiratory (28%) and
Gynecology (12%) will continue to outperform the industry. The Company has been pro-
active in launches in both these segments, while the price hikes have been undertaken
selectively in Respiratory segment. We forecast domestic formulations to grow at a
sustainable 16% CAGR over FY2013-15E.
Margin re-rating on the cards
With restructuring on exports front on the verge of completion, we believe that capex
would be minimal in FY2014E leading to improvement in operational performance. However,
we assume R&D costs to be higher at 5% of sales (vis-à-vis management's guidance of
4%) as increased pace of filings in US (on its own) and investments in technical products
like Dymista could lead to high R&D spend. Also, with Cipla increasing its focus on markets
like US and EU, we expect employee costs to rise going forward. Hence, excluding the
currency benefit, we forecast marginal expansion (20bp) in EBITDA margin in FY2014E
on a high base of FY2013E. We expect annual EBITDA margin of 25.4% and 25.9% for
FY2014E and FY2015E respectively, as exclusive supplies wane down in 2HFY2013.
Return Ratios & Asset Turnover to improve due to better utilization of Indore SEZ
Cipla has spent Rs900cr for its Indore SEZ facility, which houses facility for oral, topical
injectables and others. The compression of the return ratios and asset turnover ratios has
been in lieu of SEZ. We believe that with improving capacity utilization at the SEZ plant
and maintenance capex, the operating leverage will aid the key profitability ratios, going
This Research Report (hereinafter called 'Report') is prepared and distributed by Reliance Securities Limited (RSL) for information
purposes only. The views herein constitute only the opinions and do not constitute any guidelines or recommendation and should not be deemed or
construed to be neither advice for the purposes of purchase or sale of any security, derivatives or any other security through RSL nor any solicitation or
offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security(ies) referred to herein. These information / opinions / views
are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of
this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at
an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly
available information, internally developed data and other sources believed by RSL to be reliable. RSL or its directors, employees, affiliates or representatives
do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care
has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of
RSL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatso-
ever from the information / opinions / views contained in this Report.
Trading and investment in securities are subject market risks. There are no assurances or guarantees that the objectives of any of trading / investment
in securities will be achieved. The trades/ investments referred to herein may not be suitable to all categories of traders/investors. The names of securities
mentioned herein do not in any manner indicate their prospects or returns. The value securities referred to herein may be adversely affected by the
performance or otherwise of the respective issuer companies, changes in the market conditions, micro and macro factors and forces affecting capital markets
like interest rate risk, credit risk, liquidity risk and reinvestment risk. Derivative products may also be affected by various risks including but not limited to
counter party risk, market risk, valuation risk, liquidity risk and other risks. Besides the price of the underlying asset, volatility, tenor and interest rates may
affect the pricing of derivatives.
Disclaimers in respect of jurisdiction:
The possession, circulation and/or distribution of this Report may be restricted or regulated in certain jurisdictions by
appropriate laws. No action has been or will be taken by RSL in any jurisdiction (other than India), where any action for such purpose(s) is required.
Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all
applicable laws and regulations of such country or jurisdiction. RSL requires such recipient to inform himself about and to observe any restrictions at his own
expense, without any liability to RSL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.
Disclosure of Interest:
The research analysts who have prepared this Report hereby certify that the views /opinions expressed in this Report are their
personal independent views/opinions in respect of the securities and their respective issuers. Neither RSL nor the research analysts did have any known
direct /indirect conflict of interest including any long/short position(s) in any specific security on which views/opinions have been made, during the preparation
of this Report.
The copyright in this Report belongs exclusively to RSL. This Report shall only be read by those persons to whom it has been delivered. No
reprinting, reproduction, copying, distribution of this Report in any manner whatsoever, in whole or in part, is permitted without the prior express written
consent of RSL.
These disclaimers, risks and other disclosures must be read in conjunction with the information / opinions / views of which they form part of.
Reliance Securities Limited is a Stock Broker with Bombay Stock Exchange Limited (SEBI Registratio n Nos. INB011234839, INF011234839 and
INE011234839); with National Stock Exchange of India Limited (SEBI Registration Nos. INB231234833, I NF231234833, and INE231234833); and
with MCX Stock Exchange Limited (SEBI Registration No. INE261234833)
THE INFLUENCE OF RISPERIDONE ON COGNITIVE FUNCTIONS IN SCHIZOPHRENIA Schizophrenia is accompanied by a unique group of cognitive impairments. Impaired are: short-time and long-time memory, intelligence, mental speed, attention, precision, perception, social problem solving ability, planning and abstract reasoning. These impairments were considered a side effect of productive psychotic s
Alimera Sciences and Bausch & Lomb Announce Transaction For Alaway™ OTC Eye Care Product FOR RELEASE WEDNESDAY, DECEMBER 20, 2006 ATLANTA, GA AND ROCHESTER, NY – Alimera Sciences, a privately-held company headquartered in Atlanta, GA and Bausch & Lomb (NYSE:BOL) today announced that Bausch & Lomb has purchased Alimera’s OTC allergy franchise, including Alaway (keto